Incyte Genomics Inc (INCY)
Nasdaq · Common stock · Services-Commercial Physical & Biological Research
As of Oct 21, 2:17 PM ET15 min delayedAbout 15 minutes behind the market. Every member plan is real time.
Follow INCY in real time
Real-time quotes, Pro Charting, the scanner and the alert feed on INCY and every other US listing.
Start 5 days freeTry Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
INCY at a glance
Key statistics
$23.64B
Market capitalization
- Previous close
- $116.62
- Open
- $116.17
- Day range
- $113.57 – $116.53
- Volume
- 602.9K
- Average volume (30 sessions)
- 1.69M
- Shares outstanding
- 202.70M
- Price / earnings
- 14.7
- Earnings per share
- $7.95
- Price / book
- 3.7
- Price / sales
- 4.1
- Beta (1 year, vs SPY)
- 0.41
Where the price sits in its year
52-week range
61% of the range
- Below the 52-week high
- -14.3%
- Above the 52-week low
- +35.3%
Completed sessions through Oct 20, 2026
Technical snapshot
Below its 50-day average, above its 200-day
- 20-day average
- $116.42+0.2%
- 50-day average
- $121.59-4.1%
- 200-day average
- $107.65+8.3%
Between the conventional 30 and 70 bands.
+7.4%
1 week
-6.4%
1 month
+0.7%
3 months
+18.1%
Year to date
+33.2%
1 year
Price change over each window, from completed sessions. Past performance does not indicate future results.
Every plan: MACD, ATR, the 20- and 50-day ranges, five-year and all-history extremes and the full indicator set, live on Pro Charting.The member platform, in real time
What members do with INCY
INCY on Pro Charting
Every intraday interval in real time, the drawing kit and the full set of technical studies on INCY.
See the plans →
Every planScreen names like INCY
The real-time scanner: price, volume, technical, fundamental and chart-pattern filters across the whole US market.
See the plans →
Analysis Tools OnlySet a price line on INCY
Put INCY on your watchlist, draw the levels you care about, and My Dashboard tracks where it trades against them.
See the plans →
Stock Alerts + ToolsOpen alerts on INCY
See whether there is an open premium alert on INCY, with its entry, stop and exit, each one reviewed by an analyst before it is sent.
See the plans →
From the public news wire
INCY headlines
- Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential
Benzinga · Jun 9, 2026
- Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps
Benzinga · Mar 10, 2025
- Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeline
Benzinga · Jan 14, 2025
- 9 Analysts Have This To Say About Incyte
Benzinga · May 23, 2024
- Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Benzinga · Apr 23, 2024
- Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Benzinga · Apr 23, 2024
- Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Benzinga · Mar 12, 2024
- The Analyst Verdict: Incyte In The Eyes Of 8 Experts
Benzinga · Feb 14, 2024
SEC Form 4, most recent first
Insider filings
CAGNONI PABLO J
−423
President, Global Head of R&D · Option exercise
· Oct 15, 2026
CAGNONI PABLO J
−839
President, Global Head of R&D · Option exercise
· Oct 15, 2026
CAGNONI PABLO J
−925
President, Global Head of R&D · Option exercise
· Oct 15, 2026
CAGNONI PABLO J
+925
President, Global Head of R&D · Option exercise
$59.43K · Oct 15, 2026
CAGNONI PABLO J
+839
President, Global Head of R&D · Option exercise
$60.35K · Oct 15, 2026
CAGNONI PABLO J
−455
President, Global Head of R&D · Option exercise
· Oct 15, 2026
CAGNONI PABLO J
−2.6K
President, Global Head of R&D · Open-market sale
$297.78K · Oct 15, 2026
CAGNONI PABLO J
+423
President, Global Head of R&D · Option exercise
$26.12K · Oct 15, 2026
About Incyte Genomics Inc
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
- Exchange
- Nasdaq
- Security
- Common stock
- Industry
- Services-Commercial Physical & Biological Research
- Headquarters
- Wilmington, DE
- Employees
- 2,844
- Listed since
- Nov 3, 1993
- Website
- incyte.com
Pick the desk that fits how you trade
Analysis Tools Only for the real-time scanner, Pro Charting and the research desk. Stock Alerts + Tools for the human-reviewed alert feed. Premium Membership for both, at one price.
Try Premium Membership free for 5 days. Card required. After 5 days it is $149 per month or $1,099 per year until you cancel. First-time members only.
Other plans from $39 a month. Pay by card, Apple Pay, Google Pay, Link, Cash App Pay or Amazon Pay through Stripe.